14. LIFE BELOW WATER

Zoetis (NYSE:ZTS) Downgraded by StockNews.com to “Buy” – MarketBeat

Written by Amanda

Zoetis (NYSE:ZTS) Downgraded by StockNews.com to “Buy”  MarketBeat

Zoetis (NYSE:ZTSGet Rating) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday.

A number of other equities analysts have also recently issued reports on ZTS. Stifel Nicolaus lowered their price objective on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, June 24th. The Goldman Sachs Group dropped their price target on Zoetis from $208.00 to $202.00 and set a “buy” rating for the company in a research note on Thursday, July 21st. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Friday, August 5th. Finally, Piper Sandler assumed coverage on Zoetis in a research report on Monday, July 11th. They issued an “overweight” rating and a $205.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $224.00.

Zoetis Price Performance

ZTS stock traded down $4.25 during mid-day trading on Tuesday, hitting $152.94. The stock had a trading volume of 1,959,213 shares, compared to its average volume of 2,157,976. The firm has a fifty day simple moving average of $168.78 and a 200 day simple moving average of $174.11. The firm has a market capitalization of $71.60 billion, a P/E ratio of 34.68, a P/E/G ratio of 2.74 and a beta of 0.77. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. Zoetis has a 52 week low of $151.75 and a 52 week high of $249.27.

Zoetis (NYSE:ZTSGet Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.19 earnings per share. As a group, research analysts forecast that Zoetis will post 5.01 EPS for the current year.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 4,334 shares of the firm’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $175.00, for a total transaction of $758,450.00. Following the completion of the transaction, the executive vice president now directly owns 23,687 shares in the company, valued at $4,145,225. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Kristin C. Peck sold 311 shares of the business’s stock in a transaction on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the transaction, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 4,334 shares of the stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $175.00, for a total value of $758,450.00. Following the sale, the executive vice president now owns 23,687 shares of the company’s stock, valued at $4,145,225. The disclosure for this sale can be found here. Insiders sold a total of 16,501 shares of company stock valued at $2,949,073 in the last three months. Insiders own 0.12% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Institutional investors and hedge funds have recently made changes to their positions in the business. Horizon Investments LLC increased its stake in Zoetis by 5.5% in the fourth quarter. Horizon Investments LLC now owns 9,113 shares of the company’s stock valued at $2,220,000 after purchasing an additional 477 shares in the last quarter. Resources Management Corp CT ADV increased its position in Zoetis by 18.7% in the 1st quarter. Resources Management Corp CT ADV now owns 3,112 shares of the company’s stock valued at $587,000 after buying an additional 491 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Zoetis by 4.5% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 151,858 shares of the company’s stock worth $28,643,000 after buying an additional 6,593 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Zoetis by 6.3% in the first quarter. Revolve Wealth Partners LLC now owns 1,153 shares of the company’s stock worth $217,000 after acquiring an additional 68 shares in the last quarter. Finally, Elk River Wealth Management LLC grew its stake in Zoetis by 22.6% in the first quarter. Elk River Wealth Management LLC now owns 30,672 shares of the company’s stock valued at $5,784,000 after acquiring an additional 5,651 shares during the period. Institutional investors own 91.05% of the company’s stock.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading

Analyst Recommendations for Zoetis (NYSE:ZTS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Zoetis, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Zoetis wasn’t on the list.

While Zoetis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Source: marketbeat.com

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment